PMC9681565_01
Cell shooting of flow cytometry.
JIR2022-6285510.001.jpg
PMC9681565_01_JIR2022-6285510.001.jpg
fig1
T-cell kit; Miltenyi Biotec) before CMVST infusion as well as one week and one month after the second CMVST infusion. The proportion of IFN-gamma+CD8+ cells was 0% before CMVST infusion and 8.1% and 4.8% at one week and one month after the second CMVST infusion, respectively (Figures 1 and 2).
IFN-gamma+CD8+ cells before and after CMVST infusion.
JIR2022-6285510.002.jpg
PMC9681565_01_JIR2022-6285510.002.jpg
fig2
T-cell kit; Miltenyi Biotec) before CMVST infusion as well as one week and one month after the second CMVST infusion. The proportion of IFN-gamma+CD8+ cells was 0% before CMVST infusion and 8.1% and 4.8% at one week and one month after the second CMVST infusion, respectively (Figures 1 and 2).